Novavax says COVID vaccine for U.S. to be manufactured by India's Serum
Tweet
Share
E-mail
FILE PHOTO: Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) - Novavax Inc said on Tuesday that its COVID-19 vaccine initially available in the United States, if authorized, will be manufactured by the Serum Institute of India.
"So all vaccines that are being distributed globally commercially are being made in a single facility by our partners (the Serum Institute in India) that includes the vaccines which are being deployed around the world as well as the ones that will be initially deployed in the U.S.," said Chief Medical Officer Filip Dubovsky.
(Reporting by Manas Mishra in Bengaluru; Editing by Chris Reese)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Mexico gas pipeline for Oracle data center delayed to 2027
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Workday stock surges on Silver Lake buyout talks report
Create E-mail Alert Related Categories
FDA, General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
